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glioblastoma multiforme cobalt-60 radiation tumor localization dosimetry limited volume radiation ECENT advances in brain scanning, angiography, and neurosurgery have aided in the localization of intracranial neoplasms and justify re-examination of existing radiation techniques. In particular, the relative value of limited field versus whole brain irradiation when treating glioblastoma multiforme of the brain needs to be reassessed. We undertook this study to compare the results of these two techniques, taking into consideration the size of the area treated as well as the dose used for treatment.
Clinical Material and Methods

Random Study
In 1965 we began a clinical study of limited field versus whole brain irradiation of selected patients who had positive angiograms, a lesion well defined on the brain scan, and histological confirmation with craniotomy and gross total removal when possible. All these patients were given corticosteroids postoperatively. Several authors have shown the reliability of brain scans in the diagnosis, localization, and delineation of brain tumors, 6 and we therefore felt confident that the entire tumor volume would be included in the limited treatment port. Any treatment failure then would presumably be due to tumor persistence rather than to a "geographic miss."
Since it was unknown whether limited field or whole brain irradiation provided better results, the treatment of 34 patients in the initial study was randomized into two groups by the toss of a coin. One group of 13 patients received whole brain irradiation, and the other group of 21 patients received irradiation to the tumor volume delineated by the operative findings, angiogram, and brain scan. This treated volume was, in all cases, larger than 1000 cc. In view of anticipated tumor growth and spread across the midline via the corpus callosum in a "butterfly pattern, ''r we treated nearly all patients with cobalt-60 through parallel opposing ports. Taking into account the normal brain tissue tolerance, we gave higher doses to patients treated with a limited volume than to those treated with whole brain irradiation.
Selected Study
Before and after the randomized study there was a preference in this department for treating intracranial gliomas with localized ports in contrast to the more commonly used whole brain irradiation. Consequently, in addition to the 34 patients placed in the randomized study, we also reviewed all patients with glioblastoma multiforme who had been treated with either whole brain or limited volume technique but not included in the randomized study. There were 26 such patients, nine who received treatment to the whole brain and 17 who received limited volume treatment.
Results
Random Study
Thirteen randomized patients were treated by whole brain irradiation, with an average dose of 4398 rads DT (tumor dose) in 33 days. The average overall survival time from surgery to death, definite recurrence, or when the patients were lost to follow-up, was 8.5 months. The average interval from surgery to death was 11.6 months, and the average tumor-free period in survivors, i.e., no evidence of disease, was 11.6 months. Five patients lived longer than 1 year, and one has now been followed for 22 months with no evidence of disease (Table 1 ).
There were 21 randomized patients treated by limited volume irradiation, with an average dose of 5272 rads DT in 28 days. The average overall survival was 11.5 months. The average interval to death was 11.6 months. The average tumor-free period in survivors was 20.6 months. Five patients lived longer than 1 year, and two lived longer than 2 years (Table 2 ). (They did not do as well as those patients selected for localized frontal lobe irradiation described below. )
Patients in the randomized group with frontal lobe lesions treated with limited volume irradiation (Table 2) had the following average survivals: frontal lobe 14.1 months (10 patients) parietal lobe 10.25 months ( 4 patients) temporal lobe 5.7 months ( 6 patients) posterior fossa 30 months ( 1 patient )
Selected Study
Of the 26 selected patients with glioblastoma multiforme, nine had received irradiation to the whole brain; the average dose was 4435 rads DT in 38 days. The average survival time was 8.2 months. Two of these patients lived longer than 1 year ( Table 1 ) . The 17 patients treated with the limited volume technique received an average dose of 4815 rads DT in 36 days. The average survival was 20.4 months. Ten patients lived longer than 1 year, six lived longer than 2 years, and three lived longer than 3 years. At the last follow-up, one is still alive at 4 years 4 months and one at 6 years 4 months after treatment (Table 2) .
Those selected for small field treatment were the most favorable patients as far as known prognostic signs, i.e., a well-localized frontal lobe lesion and an otherwise healthy patient. The importance of selection in influencing this difference in survivals is emphasized by the significantly shorter survival times noted in Table 2 of the randomized patients. The patients selected for and treated with whole brain irradiation (Table 1 ) showed survival times similar to those treated with whole brain irradiation in the randomized group.
We reviewed all available autopsy material on the patients in this study and found that in those patients where tumor persisted it was within the treated volume. Therefore, we feel that recurrence is related to the resistance of the tumor itself rather than a geographic miss. In addition, these areas of persistence were also documented by repeat brain scans and angiograms in a large per cent of the patients. The patients with frontal lobe tumors selected for limited volume irradiation (Table 2) had the best average overall survival:
frontal lobe 24 months (7 patients) parietal lobe 13 months (7 patients) temporal lobe 47 months (2 patients, 1 lived 90 months) posterior fossa 12 months ( 1 patient ).
Discussion
Before brain scanning became routinely available, Concannon, et al., ~ in 1960, summarized the results obtained in 21 patients with supratentorial gliomas. All 21 died shortly after radiation therapy, and all had autopsies performed. The tumor was considered missed if a portion of the tumor, or a 1 cm margin, was definitely within the treated zone. Of the 21 cases only two were felt to have had the entire tumor included in the treated volume. Eleven had questionable tumor coverage, and in eight the tumor was missed entirely. Pathological examination revealed that the tumors were almost invariably more extensive than originally suspected. In view of these findings, they recommended that a large field be used, i.e., greater than 800 cc or 12 x 9 x 8 cm.
Todd 9 reviewed 23 cases of supratentorial glioblastoma multiforme. His results showed that those patients treated with large volumes, i.e., greater than 500 cc or an 8x 8 x 8 field, did significantly better than those treated with more limited volumes. All of his patients were irradiated over a nominal 3-week period. Ignoring volume, he found no significant difference between the low and high dose levels, i.e., those given 4500 fads or less and those over 4500 rads. all were dead in 6 months. With partial removal, 86% were dead in 6 months and 96% were dead in 12 months. Of those with biopsy followed by irradiation, 50% were alive 6 months after biopsy. Of those who received partial removal followed by irradiation, 86% were alive at 6 months. The patients received widely varying doses of radiation, and the total dose did not seem to be a significant factor in the length of survival. It appeared that radiation prolonged survival in those patients who lived at least 30 days postoperatively, but even this conclusion is clouded by the type of selection that was associated with the high irradiation dose.
The selection of treatment volume is always dependent on a clinical assessment of tumor extent and probable pathways of spread. The dose delivered to the selected volume is limited by the radiation tolerance of the most critical tissue in the volume. Reducing this volume may permit an increased dose by partly or completely eliminating a sensitive critical tissue. This is of special interest in the treatment of glioblastoma multiforme where the ability to give a high dose may be severely limited by the sensitive non-neuronal tissues of the brain. The radiation tolerance of the frontal lobe cortex and the brain stem is vastly different; necrosis or even amputation of the former is compatible with survival whereas the sensitive brain stem is a critical tissue for survival.
The results of our study show that it is possible, by using brain scanning, angiography, and operative examination, to define a limited volume to be irradiated and that improved survival may be achieved by delivering higher doses in that volume. We now favor use of a limited volume and the highest possible dose: 6000 rads DT (tumor dose) over 6 weeks. If localization is less certain, the whole brain can be irradiated to 4000 rads DT and the apparent volume given an additional 1500 to 3000 rads DT depending on the site selected.
While we realize that the number of patients in each of our groups is not large, the trend appears to be an accurate reflection of the survival in these cases. It appears that longer survival is also related to the anatomical position of the tumor, and it is very possible that in the future the anatomical position of the tumor will play a part in the staging of the disease and in more exact treatment.
Summary
For glioblastoma multiforme patients receiving whole brain irradiation, whether selected for treatment or picked at random, the average overall survival (i.e., time to death, definite recurrence in survivors, or lost to follow-up) was about 81 months. Among patients selected for limited volume irradiation, the average survival was 20.4 months.
A higher dose delivered to a smaller volume resulted in a longer survival time.
The site of the lesion favorably influenced the survival time; patients with frontal lobe lesions had a significantly longer survival time than those with lesions in other areas of the brain. Finally, patients may be reliably selected for limited volume irradiation without fear of missing the area of the tumor mass.
